삼국유사 건국신화에 나타난 신성분류와 계승성

오태권 ( Tae Kwon Oh ) 택민국학연구원 2015 국학연구론총 Vol.0 No.16

신성과 세속은 사실상 인간 내면의 정서를 드러내는 방식으로, 가장 불완전하고 광범위한 정의가 가능하다. 또한 역사화 된 인간 곧, 문명적으로 변해가는 인간이 역으로 과거를 규정하는 방식이 성과 속의 개념이다. 이를 지식체계 속에 저장하여 후대에 전승하는 방식이 곧 신화이다. 그러므로 신화는 성과 속의 발생과 변화의 과정을 올바르게 분류하고 분석할 때 신화에 나타난 당대 인간들의 인식을 제대로 읽어낼 수 있다. 본고는 신화가 가지고 있는 여러 가지 속성 중에서 문학과 역사가 충돌하는 지점을 중요하게 본다. 신화의 역사화는 전승 주체가 뚜렷하게 존재하는데, 이들이 건국 혹은 씨족 형성 과정에서 실제 경험했던 사실을 역사로 정리하는 방식으로 신화화가 발전하기 마련이다. 이에 비해 문학화는, 전승집단이 뚜렷하게 존재하지 않았거나 후대에 전승집단이 약화되고 소멸되는 과정에서 이야기만 남아 문학으로 정리되는 방향으로 신화가 발전하였을 것이다. 본고는 이러한 과정을 중심으로 신화가 어떻게 신성성을 획득해 가는지, 그리고 어떠한 과정을 거치면서 신성성을 상실해 가는지 그 원리를 『삼국유사』「기이」편의 서사를 통해 해명하려고 한다. 필자는 이 연구를 토대로, 궁극적으로 우리문학이 가지고 있는 중심의 문제, 즉 우리가 계승하고 있는 서사문학의 전통이 신화로부터 유래했다면 신화의 어떠한 측면이 이러한 전통을 계승하게 했는지 밝히고자 한다. 즉 신화가 어떤 과정을 통하여 당시 고대인들의 삶에서 파생되어 문학적 서사로 정착될 수 있었는지 그 원리를 해명하고자하는 것이다. 본고에서는 신화서사에서 이러한 신성관념의 생성 국면과 존재 국면을 드러내는 표지로써 각각의 조건들을 신성서사에서 추출하여 밝히려고 한다. 이러한 생성과 존재의 조건들의 변화가 곧 신성과정이며, 신성성의 발생과 상실의 문제이기 때문이다. 본고는 위의 원리들을 적용하여 삼국유사를 바탕으로, 건국신화에 나타난 인물들과 개인적인물의 신성서사를 자료로 삼아 어떤 집단의 의식에 의해서 신화화되며, 어떠한 세계관에 의해서 생성과 성장, 소멸을 겪는지 『삼국유사』「기이」편에 나타난 신성서사를 통해 그 원리를 밝히려 한다. Sacredness and secularity, as the ways that virtually reveal the internal sentiments of human beings, can be defined in the most incomplete and broadest way. In addition, historicized and then civilized human beings utilize them to define their pasts inversely. A myth is the way to keep them in the structure of knowledge and pass them to the future generation. Therefore, it is possible to properly understand the thoughts of the people living in the time, which was melted in myths when we correctly classify and analyze the process of the generation and development of divinity and secularity. This study in particular focuses on the point of the collision between literature and history among the many characteristics of myths. The main groups who were responsible for historicizing and transmitting myths could be explicitly identified, as these people tended to include what they had experienced during the course of forming a clan society or founding a country into their history, which also explains the process of mythicization. On the contrary, it is assumed that only the tale part of myths were developed into literature as either there were no transmission groups or once-existed transmission groups were diminished or disappear in later days. In this study, I intend to explain how myths acquired sacredness and later lost it again by analyzing the description of the [Gii] section of Samguk yusa (Memorabilia of the Three Kingdoms) and furthermore, based on the result of the analysis, one of the essential questions of our literature, that is, what parts of myths, if the tradition of our narrative literature was originated from myths, have been inherited to literature. In other words, this study aims at researching the principal causes of how myths were originally created from the life of ancient people and developed as a part of literary description. In addition, I will extract and analyze from scared narratives the conditions that reveal the generation and existence of such sacred idea in mythical narratives. For the change of the conditions for generation and existence was the course of sacralization and indicated the matter of the production and loss of sacredness. This study will present an explanation about how the figures shown in the birth myths of nations and other individuals written in [Gii] section of Samguk yusa were included in myths by what group’s thoughts and what view of the world was responsible for the creation, developing and disappearing of them.

한국형 유산균 Bifidobacterium 속 균주의 항생물질에 대한 감수성

장현아,최금화,오태권,권애란,김동현,최응칠,Chang, Hyun-Ah,Choi, Keum-Hwa,Oh, Tae-Kwon,Kwon, Ae-Ran,Kim, Dong-Hyun,Choi, Eung-Chil 대한약학회 1998 약학회지 Vol.42 No.6

Minimal inhibitory concentrations (MICs) of Bifidobacterium spp. strains (Bifidobacterium breve K-110, B. breve K-111 and B. infantis K-525) isolated from healthy Korean against antituberculosis agents and fluoroquinolones were determined. From the MICs it was found that Bifidobacterium breve K-110, B. breve K-111 and B. infantis K-525 were susceptible to rifampicin and fluoroquinolenes and resistant to other antituberculosis agents.

새로운 퀴놀론 항균제 DW-116의 살균 작용

최금화(Keum Hwa Choi),오태권(Tae Gwon Oh),권애란(Ae Ran Kwon),김병각(Byong Kak Kim),최응칠(Eung Chil Choi) 대한약학회 1999 약학회지 Vol.43 No.1

The bactericidal activities of DW-116, a new fluoroquinolone was estimated by comparing the minimal bactericidal concentrations (MBCs) of it against some Gram-positive and -negative bacterial concentration with the minimal inhibitory concentrations (MICs). The MBCs against the test organisms were equal to or two times higher than MICs. The results support that the antibacterial activity of DW-116 is bactericidal.

새로운 퀴놀론 항균제 DW-116의 Post-Antibiotic Effect

최금화(Keum Hwa Choi),오태권(Tae Kwon Oh),백문창(Moon Chang Baek),김병각(Byung Kak Kim),최응칠(Eung Chil Choi) 대한약학회 1998 약학회지 Vol.42 No.2

The post-antibiotic effects (PAE) of DW-116 were evaluated against Bacillus subtilis ATCC 6633, Bacillus cereus ATCC 27348, Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922 and Pseudomonas aeruginosa MB4-16, repectively. Against gram-positive bacteria, PAEs of DW-116 were longer duration (20-35 min) than those of rufloxacin(1O-20 min), and shorter than those of ciprofloxacin (50-90 min). Especially, against E. coli, DW-116 and ciprofloxacin obtained approximately 3 hrs of PAES.

리팜피신과 오플록사신에 내성인 Bacillus coagulans OFR17 균주

김은아(Eun Ah Kim),오태권(Tae Kwon Oh),최금화(Keum Hwa Choi),이진희(Jin Hee Lee),백문창(Moon Chang Baek),김병각(Byong Kak Kim),최응칠(Eung Chil Choi) 대한약학회 1997 약학회지 Vol.41 No.4

The preparation of Bacillus coagulans is used as a therapeutics for human intestinal disorders. However, the bacterium in the preparation is very susceptible to rifampicin and fluoroquinolones. When the preparation is taken with rifampicin or fluoroquinolones, its therapeutic effect can not be expected. So B. coagulans RFR17 resistant to rifampicin was obtained by treating the parent B. coagulans with N-methyl-N'-nitro-N-nitrosoguanidine. B. coagulans OFR17 was produced by serial passage of B. coagulans RFR17 on agar with 2-fold minimal inhibitory concentration of ofloxacin or ciprofloxacin. B. coagulans OFR17 was resistant to fluoroquinolones up to 16~64 fold higher than that for the original strain. B. coagulans OFR17 also exhibited identical characteristics with the parent strain when they were tested for lactic acid production and growth inhibition of E. coli MB4-01 and Shigella sonnei MB4-10411. From in vitro test, it was also identified that rifampicin and ofloxacin are not inactivated by certain factors of B. coagulans OFR17. Conclusively, B. coagulans OFR17 can be regarded as a promising strain which can be developed as the preparation for the treatment of the intestinal disorders of the tuberculosis patients under rifampicin and ofloxacin therapy.

리팜피신과 플로로퀴놀론계 항생균제에 내성인 Bifidobacterium infantis OFR-525 균주

장현아(Hyun Ah Chang),권애란(Ae Ran Kwon),오태권(Tae Kwon Oh),김동현(Dong Hyun Kim),최응칠(Eung Chill Choi) 대한약학회 1999 약학회지 Vol.43 No.1

Bifidobacterium infantis K-525 isolated from healthy Korean was susceptible to rifampicin and fluoroquinolones and resistant to other antituberculosis agents. When the preparation of this strain is taken as a therapeutics for human intestinal disorders with rifampicin or fluoroquinolones, its therapeutic effect can not be expected. So, B. infantis RFR-525 resistant to rifampicin was obtained by treating the parent B. infantis 525 with N-methyl-N`-nitro-N-nitrosoguanidine. B. infantis OFR-525 was produced by serial passage of B. infantis RFR-525 on agar with 2-fold minimal inhibitory concentration of ofloxacin. B. infantis OFR-525 was resistant to antituberculosis agents and fluoroquinolones up to 4-128 fold higher than that for the original strain. The resistance of B. infantis OFR-525 against rifampicin and ofloxacin was maintained in vivo and in vitro. Conclusively, B. infantis OFR-525 can be regarded as a promising strain which can be developed as the preparation for the treatment of the intestinal disorders of the tuberculosis patients under rifampicin and ofloxacin therapy.